DOJ Reclassifies Marijuana to Schedule III, Easing Tax Burdens and Boosting Research

The U.S. Department of Justice has officially moved to reclassify marijuana as a Schedule III drug, acknowledging its medical uses and lower potential for abuse compared to Schedule I substances.

This change primarily benefits the legal cannabis industry by removing the restrictive 280E tax code, allowing businesses to deduct standard operating expenses for the first time.

However, this action does not legalize recreational marijuana at the federal level; it remains a controlled substance, and state-level adult-use markets are still federally illegal.

The U.S. government has made a landmark decision to reclassify marijuana, a move that will reshape the medical cannabis industry.

For decades, marijuana has been listed as a Schedule I drug under the Controlled Substances Act, alongside substances like heroin. This classification signified a high potential for abuse and, crucially, 'no currently accepted medical use.' The Department of Justice's (DOJ) decision moves it to Schedule III, a category for drugs with a moderate to low potential for dependence and accepted medical applications, like ketamine or Tylenol with codeine. This is a significant shift in federal drug policy.

The most immediate and impactful change is financial. The reclassification frees state-legal cannabis businesses from the Internal Revenue Code's Section 280E. This tax provision, which applied only to traffickers of Schedule I or II substances, prohibited them from deducting ordinary business expenses like rent, payroll, and marketing. This created a heavy financial burden, with effective tax rates sometimes exceeding 70%. With 280E no longer applicable, these companies can operate more like traditional businesses, potentially saving hundreds of thousands of dollars annually and improving their cash flow significantly.

This decision didn't happen overnight; it's the result of a multi-year administrative process. First, the journey began in August 2023 when the Department of Health and Human Services (HHS) conducted a scientific review and formally recommended that the Drug Enforcement Administration (DEA) reschedule marijuana. Second, this prompted the DOJ to issue a notice of proposed rulemaking in May 2024, initiating a lengthy period of public comment and legal review. Third, an executive order in late 2025 accelerated the process, culminating in this final rule.

It is important to understand what this change does not do. It does not legalize recreational cannabis nationwide. The state-run markets for adult-use marijuana remain illegal under federal law. The reclassification primarily recognizes its medical value and eases regulations around research and prescribing, while providing critical tax relief to an industry that has long operated in a legal gray area.

Glossary
Schedule III Drug: A substance with a currently accepted medical use and a moderate to low potential for physical and psychological dependence. It is less stringently regulated than Schedule I and II drugs.
IRC §280E: A section of the U.S. Internal Revenue Code that forbids businesses from deducting otherwise ordinary business expenses from gross income associated with the "trafficking" of Schedule I or II controlled substances.

DOJ Reclassifies Marijuana to Schedule III, Easing Tax Burdens and Boosting Research

The U.S. Department of Justice has officially moved to reclassify marijuana as a Schedule III drug, acknowledging its medical uses and lower potential for abuse compared to Schedule I substances.

This change primarily benefits the legal cannabis industry by removing the restrictive 280E tax code, allowing businesses to deduct standard operating expenses for the first time.

However, this action does not legalize recreational marijuana at the federal level; it remains a controlled substance, and state-level adult-use markets are still federally illegal.

The U.S. government has made a landmark decision to reclassify marijuana, a move that will reshape the medical cannabis industry.

Glossary
Schedule III Drug: A substance with a currently accepted medical use and a moderate to low potential for physical and psychological dependence. It is less stringently regulated than Schedule I and II drugs.
IRC §280E: A section of the U.S. Internal Revenue Code that forbids businesses from deducting otherwise ordinary business expenses from gross income associated with the "trafficking" of Schedule I or II controlled substances.